Our annual Fierce 15 report on a top class of up-and-coming private biotechs came out today and I wanted to highlight the responses from many of the companies which are on the list. Read more | Check out this year's report
Last year when Ryan McBride and I were sorting through our short list of candidates, we both felt that Seaside Therapeutics deserved a spot on the list. The small company had raised a considerable...
Kala Pharmaceuticals is developing a novel way to get drugs into the eye, and the company notched some positive results in preclinical studies, finding that its platform led to higher drug concentration for a retinal treatment.
Boston startup Entrega is developing a novel drug-delivery capsule that could give the company a foothold in a $200 billion arena just begging for more needle-free options, paving the way for the more elegant delivery of treatments for diseases such as Parkinson's, cancer and arthritis.
The new CEO at Kala Pharmaceuticals has landed an $11.5 million A round and mapped out plans to devote much of the cash to lead programs on wet, age-related macular degeneration and ocular inflammation.
Kala Pharmaceuticals received a grant from the Cystic Fibrosis Foundation to demonstrate that the company's mucosal-barrier-penetrating nanoparticle can do the same across bacterial biofilms, a symptom of cystic fibrosis.
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it...
Mucosal delivery company Kala Pharmaceuticals has welcomed Guillaume Pfefer, ex-general manager of Sanofi Pasteur Mexico, as its new president and CEO. Kala's co-founder, Justin Hanes, has published data on the company's mucosal-penetrating products (MPPs) in Science Translational Medicine.
The startup biotech Kala Pharmaceuticals has taken another step forward in its journey to the clinic. The Waltham, MA-based developer of mucus-penetrating particle treatments--one of Robert Langer's portfolio of startups--has wooed Gillaume Pfeffer into the top spot.
An upstart biotech company with intriguing new formulation technologies and a roster of influential backers has rounded up $6.2 million in additional seed capital.